Diffusion adds Isaac Blech to board of directors
Mr. Blech, an experienced biotechnology entrepreneur and investor, brings to Diffusion over 35 years of expertise in the biotech industry.
Mr. Blech has founded and served on the board of a number of companies that have produced major advances in a broad array of diseases, including the diagnosis of chlamydia, herpes, syphilis and HIV, and the treatment of cystic fibrosis, sexual dysfunction, multiple myeloma and many forms of cancer and hematological disease.
Among the companies he has established are Celgene Corporation, ICOS Corporation, purchased by Eli Lilly, Nova Pharmaceutical Corporation, Gliadel, purchased by Johnson & Johnson, Pathogenesis Corporation, purchased by Chiron, and Genetics Systems Corporation, later purchased by Bristol-Myers Squibb.
Among the boards Mr. Blech currently serves on are Cerecor, Inc., a CNS company, ContraFect Corporation, an infectious disease company, Medgenics, Inc., a biotechnology company, and Edge Therapeutics, Inc., a company that treats life-threatening neurological conditions. ■
LATEST MOVES FROM Virginia
- InSite Wireless Group appoints Bob Johnson as COO
- Command Security appoints Jerry L. Johnson to board
- PRA Group appoints Kevin Stevenson as CEO
- Northrop Grumman appoints new aerospace executive
- Dominion Midstream appoints two new directors
More inside POST
New CEOs have 100 days to boost stock prices Leadership